Cardiovascular safety of non-steroidal anti-inflammatory drugs in chronic inflammatory rheumatic diseases

被引：5
作者：
Zavodovsky, B. V. [1 ]
Sivordova, L. E. [1 ]
机构：
[1] AB Zborovsky Res Inst Clin & Expt Rheumatol, Volgograd, Russia
来源：
TERAPEVTICHESKII ARKHIV | 2018年 / 90卷 / 08期
关键词：
cardiovascular diseases; cardiovascular risk; rheumatic diseases; rheumatoid arthritis; systemic lupus erythematosus; psoriatic arthritis; ankylosing spondylitis; chronic inflammation; non-steroidal anti-inflammatory drugs; ANKYLOSING-SPONDYLITIS; MYOCARDIAL-INFARCTION; COX-2; INHIBITORS; RISK-MANAGEMENT; ARTHRITIS; ETORICOXIB; MORTALITY; EVENTS; CELECOXIB; NAPROXEN;
D O I：
10.26442/terarkh2018908101-106
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Rheumatic diseases (RD), such as rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, psoriatic arthritis, vasculitis, gout are associated with increase in cardiovascular morbidity and mortality. The main causes of increased cardiovascular risk are inflammatory heart and vascular lesions, accelerated progression of atherosclerosis and side effects of drug therapy. Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used in clinical practice and are on the list of the most prescribed medications. It is known that NSAIDs have a negative effect on the cardiovascular system (CVS). However NSAIDs may decrease the intensity of inflammation, which is an independent risk risk factor for CVS pathology. Therefore in patients with RD it is theoretically possible to reduce the severity of cardiovascular side effects when using NSAIDs. The article discusses the issues of NSAID's cardiovascular safety, the molecular mechanisms underlying the negative effect of them on CVS, critically evaluated the results of main studies concerning the cardiovascular safety of NSAIDs in chronic inflammatory diseases.
引用
收藏
页码：101 / 106
页数：6
相关论文
共 65 条
  • [1] EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update
    Agca, R.
    Heslinga, S. C.
    Rollefstad, S.
    Heslinga, M.
    McInnes, B.
    Peters, M. J. L.
    Kvien, T. K.
    Dougados, M.
    Radner, H.
    Atzeni, F.
    Primdahl, J.
    Sodergren, A.
    Jonsson, S. Wallberg
    van Rompay, J.
    Zabalan, C.
    Pedersen, T. R.
    Jacobsson, L.
    de Vlam, K.
    Gonzalez-Gay, M. A.
    Semb, A. G.
    Kitas, G. D.
    Smulders, Y. M.
    Szekanecz, Z.
    Sattar, N.
    Symmons, D. P. M.
    Nurmohamed, M. T.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (01) : 17 - 28
  • [2] Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study
    Arfe, Andrea
    Scotti, Lorenza
    Varas-Lorenzo, Cristina
    Nicotra, Federica
    Zambon, Antonella
    Kollhorst, Bianca
    Schink, Tania
    Garbe, Edeltraut
    Herings, Ron
    Straatman, Huub
    Schade, Rene
    Villa, Marco
    Lucchi, Silvia
    Valkhoff, Vera
    Romio, Silvana
    Thiessard, Frantz
    Schuemie, Martijn
    Pariente, Antoine
    Sturkenboom, Miriam
    Corrao, Giovanni
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2016, 354 : i4857
  • [3] Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib
    Back, Magnus
    Yin, Li
    Ingelsson, Erik
    [J]. EUROPEAN HEART JOURNAL, 2012, 33 (15) : 1928 - 1933
  • [4] Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials
    Bhala, N.
    Emberson, J.
    Merhi, A.
    Abramson, S.
    Arber, N.
    Baron, J. A.
    Bombardier, C.
    Cannon, C.
    Farkouh, M. E.
    FitzGerald, G. A.
    Goss, P.
    Halls, H.
    Hawk, E.
    Hawkey, C.
    Hennekens, C.
    Hochberg, M.
    Holland, L. E.
    Kearney, P. M.
    Laine, L.
    Lanas, A.
    Lance, P.
    Laupacis, A.
    Oates, J.
    Patrono, C.
    Schnitzer, T. J.
    Solomon, S.
    Tugwell, P.
    Wilson, K.
    Wittes, J.
    Baigent, C.
    Adelowo, O.
    Aisen, P.
    Al-Quorain, A.
    Altman, R.
    Bakris, G.
    Baumgartner, H.
    Bresee, C.
    Carducci, M.
    Chang, D-M.
    Chou, C-T.
    Clegg, D.
    Cudkowicz, M.
    Doody, L.
    El Miedany, Y.
    Falandry, C.
    Farley, J.
    Ford, L.
    GarciLosa, M.
    Gonzalez-Ortiz, M.
    Haghighi, M.
    [J]. LANCET, 2013, 382 (9894) : 769 - 779
  • [5] Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis.
    Bombardier, C
    Laine, L
    Reicin, A
    Shapiro, D
    Burgos-Vargas, R
    Davis, B
    Day, R
    Ferraz, MB
    Hawkey, CJ
    Hochberg, MC
    Kvien, TK
    Schnitzer, TJ
    Weaver, A
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (21) : 1520 - 1528
  • [6] Population-Based Estimates of Common Comorbidities and Cardiovascular Disease in Ankylosing Spondylitis
    Bremander, Ann
    Petersson, Ingemar F.
    Bergman, Stefan
    Englund, Martin
    [J]. ARTHRITIS CARE & RESEARCH, 2011, 63 (04) : 550 - 556
  • [7] Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial
    Bresalier, RS
    Sandler, RS
    Quan, H
    Bolognese, JA
    Oxenius, B
    Horgan, K
    Lines, C
    Riddell, R
    Morton, D
    Lanas, A
    Konstam, MA
    Baron, JA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (11) : 1092 - 1102
  • [8] Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison
    Cannon, Christopher P.
    Curtis, Sean P.
    FitzGerald, Garret A.
    Krum, Henry
    Kaur, Amarjot
    Bolognese, James A.
    Reicin, Alise S.
    Bombardier, Claire
    Weinblatt, Michael E.
    van der Heijde, Desiree
    Erdmann, Erland
    Laine, Loren
    [J]. LANCET, 2006, 368 (9549) : 1771 - 1781
  • [9] Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis
    Choy, Ernest
    [J]. RHEUMATOLOGY, 2012, 51 : V3 - V11
  • [10] Characterization of etoricoxib, a novel, selective COX-2 inhibitor
    Dallob, A
    Hawkey, CJ
    Greenberg, H
    Wight, N
    De Schepper, P
    Waldman, S
    Wong, P
    DeTora, L
    Gertz, B
    Agrawal, N
    Wagner, J
    Gottesdiener, K
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 43 (06) : 573 - 585
1234567